Hypertension is associated with impaired fibrinolysis. Both angiotensin receptor blockers (ARB) and the DASH (Dietary Approaches to Stop Hypertension) diet effectively lower blood pressure in hypertensive patients. Some evidence suggests that treatment with ARBs could increase fibrinolysis, however, data is conflicting. The impact of the DASH diet on fibrinolytic parameters is not known. Fifty-five hypertensive participants (35 African-American, 20 white) were randomly assigned to receive 8 weeks of either a control diet or the DASH diet. The diets did not differ in sodium content (approximately 3 g/day). Within each diet, individuals were randomly assigned to receive losartan or placebo for 4 weeks in double-blind, cross-over fashion. Tissue plasminogen activator (t-PA) antigen, t-PA activity, plasminogen activator inhibitor-1 (PAI-1) activity and plasma renin activity (PRA) were measured at the end of a 2-
Introduction
Inhibition of angiotensin II (AII) activity, either through AII converting enzyme inhibition or AII receptor blockade, reduces morbidity and mortality in a variety of settings. [1] [2] [3] [4] Furthermore, the benefit may not be limited to the degree of blood pressure (BP) reduction achieved. 5 One possible explanation for these findings is that inhibition of AII activity favourably affects coagulation and fibrinolytic pathways. For example, AII receptor blockade reduces platelet activity in hypertensive subjects. 6, 7 These data suggest an anti-thrombotic effect of losartan in the hypertensive syndrome. Several studies have demonstrated a relationship between the renin angiotensin system (RAS) and the fibrinolytic system, which also has been associated with future risk of cardiovascular events. [8] [9] [10] [11] [12] Infusion of AII has been shown to increase circulating plasminogen activator inhibitor-1 (PAI-1) antigen levels in humans, 13 suggesting that increased levels of AII could reduce fibrinolytic capacity. However, data regarding the effect of angiotensinconverting enzyme (ACE) inhibition and AII receptor blockade on fibrinolytic parameters are inconsistent. [14] [15] [16] [17] A reduction in t-PA antigen levels could be important because elevated t-PA antigen levels have been associated with an increased risk of myocardial infarction and stroke, and in epidemiologic studies t-PA antigen is a stronger predictor of adverse events
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14 However, there are no data in hypertensive individuals. Furthermore, it is not known whether AfricanAmericans, who are generally less responsive to AII inhibition than whites, 21 would experience a similar degree of t-PA antigen reduction as white subjects.
Modification of dietary patterns can have powerful effects on BP and other markers of cardiovascular disease risk. In the Dietary Approaches to Stop Hypertension (DASH) trial, the DASH diet substantially lowered BP compared with a typical American diet. 22 The DASH diet has also been shown to protect against lipid peroxidation 23 and reduce homocysteine levels. 24 However, the effect of the DASH diet on fibrinolytic markers is unknown. Several smaller dietary studies have examined the impact of low-fat diets, fatty acid composition and weight loss on fibrinolytic parameters, but results were inconsistent. [25] [26] [27] [28] [29] There is some suggestion that a low-fat diet could be beneficial in terms of reducing thrombotic potential; however, it is not clear that sodium intake and body weight, two potentially important determinants, were adequately controlled in these studies.
In this setting, we evaluated the effects of losartan and the DASH diet on plasma markers of endogenous fibrinolysis. In a previous report from this trial, both interventions significantly reduced BP, with greater reductions seen in white subjects with losartan and in African-Americans with the DASH diet. Because RAS activity tends to be higher in whites 30 compared with African-Americans and because the DASH diet may lower BP to a greater extent in African-Americans, 31 we evaluated the effects of these interventions on markers of fibrinolysis by race and tested the effects after adjusting for changes in BP.
Materials and methods
This trial was a multicentre feeding study conducted at three sites, Duke University, Brigham and Women's Hospital and Johns Hopkins University, USA. Institutional review boards at each site reviewed and approved the trial protocol. Each participant provided written informed consent.
Study participants
Participants were either not taking antihypertensive medication or agreed to undergo supervised withdrawal of antihypertensive medication for 2 weeks prior to screening. Individuals 22 years of age or older were eligible if they had an average diastolic BP (DBP) between 90-109 mm Hg (JNV-VI Stages 1 and 2) and systolic BP (SBP) Ͻ180 mm Hg on two separate occasions at least 1 week apart. Exclusion criteria were a cardiovascular event within 6 months prior to study entry; renal insufficiency; unstable asthma or chronic obstructive pulmonary disease (COPD); hypo-or hypercalcaemia; gastrointestinal disorders that interfere with dietary compliance or absorption; anaemia; an alcoholic beverage intake of more than 14 drinks per week; the use of medications (including non-steroidal anti-inflammatory medications) that affect BP; and unwillingness or inability to be withdrawn from existing BP medications. All of the 55 randomised participants (35 African-American, 20 white) completed the trial. Figure 1 displays an outline of the trial. Eligible participants were withdrawn from all BP-lowering medications under close medical supervision over a 2-week, pre-baseline period. After medication withdrawal, participants had two screening visits, at least 1 week apart, at which eligibility was ascertained. Participants then started a 2-week run-in period, during which they received the control diet.
Conduct of the trial and sample collection
Following run-in, individuals were randomised to either continuation of the control diet or the DASH diet for 8 weeks. All meals were provided to participants by each of the clinical centres; one meal each was eaten at the research site. Body weight was held constant during the trial by adjusting caloric intake as needed. Within each diet arm, participants received losartan (50 mg) or a matching placebo for 4 weeks each in a crossover fashion.
Blood pressure measurements were taken with participants in the seated position by trained technicians using a standard mercury manometer and an appropriate cuff size for each participant. Participants were seated for at least 5 min prior to the BP measurement being taken. Diastolic BP was taken as the fifth Korotokoff sound (K V). Measurements were taken at each of two baseline visits and weekly thereafter during the intervention periods. At the conclusion of each 4-week intervention period, clinic BP was measured on 2 separate days. For the present study we used only the average of BPs taken at baseline and at the end of each intervention period.
Weight was monitored on a daily basis throughout the intervention, and calories were adjusted in order to avoid weight changes. Blood samples were obtained at the end of run-in and after each drug treatment period. All samples were collected using minimal venostasis, in the morning after an overnight fast and after 30 min of undisturbed sitting. Plasma for measurement of t-PA and PAI-1 activities was collected in pre-acidified tubes (Stabilyte Biopool International). Plasma for measurement of t-PA antigen was collected in 5% sodium citrate. Plasma renin activity (PRA) in ng/ml/h was measured from blood samples collected in EDTA. All samples were immediately centrifuged at 3000 g for 15 min and stored at −70°C for less than 6 months prior to assay. Personnel blinded to treatment assignments analysed all samples in duplicate.
Dietary intervention
The DASH diet has been described in detail elsewhere. 32 Compared with the control diet the DASH diet is lower in total and saturated fats and higher in fruits, vegetables and low-fat dairy products. The sodium content of each diet was similar, approximately 3 g per day at the 2100 kcal level. All meals were provided for participants for the duration of the study and participants were required to eat one meal on site during weekdays.
Statistical analysis
Results are presented as mean changes from run-in for diet effects and mean changes from placebo for losartan effects. Comparisons of baseline characteristics were made using Student's t-test for continuous data and Chi-square tests for categorical data. Race was self-defined. Racial differences in run-in levels of fibrinolytic factors were analysed using multiple linear regression after adjusting for gender, age, body mass index (BMI) and DBP. The distribution of PRA was right skewed, hence, we log transformed PRA values for all analyses. Data collection were complete for all plasma markers during the intervention periods. No significant diet/losartan interactions were present; thus, diet and losartan effects are presented separately. Data analyses were performed on an 'intention-to-treat' basis.
Generalised estimating equations (GEE) models were used to account for the within-person correlation with repeated measures of fibrinolytic factors using the xtgee procedure in STATA, release 7.0 (College Station, TX, USA). Models for losartan effects contained terms for period and carry over effects according to the method of Zeger and Liang. 33 All models included terms for baseline values of the dependent variable. In order to account for baseline differences between racial groups in subgroup
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Post-hoc power calculations for our primary outcome, t-PA antigen, showed that for treatment with losartan we had 80% power to detect a 17% change in t-PA antigen and 80% power to detect a 35% change in t-PA antigen from the DASH diet.
Results

Baseline characteristics
Diet groups were similar with regard to baseline characteristics and run-in levels of fibrinolytic factors (Table 1) . At the end of run-in, after 2 weeks on the control diet, white subjects had significantly higher t-PA antigen (10.6 ng/mL vs 7.9 ng/mL, P = 0.02) and PRA (1.06 ng/mL/h vs 0.43 ng/mL/h, P = 0.01) compared with African-Americans ( Table 2 ). There were no differences in t-PA activity or PAI-1 activity between African-Americans and white subjects at the end of run-in. There were no differences in baseline systolic or diastolic BPs between diet groups or between African-Americans and white subjects at baseline. After adjusting for age, gender, BMI and DBP, white subjects still had higher levels of plasma t-PA antigen than African-Americans (P = 0.03). PRA levels remained significantly higher in whites after adjusting for age, gender and BMI (P = 0.009), but these differences were not significant after additional adjustment for DBP (P = 0.3).
Blood pressure
There was no significant interaction between treatment with losartan and the DASH diet. Treatment with losartan resulted in a significant reduction in systolic (−9.3 mm Hg ± 1.6, P value Ͻ0.001) and diastolic (−4.9 mm Hg ± 1.0, P value Ͻ0.001) BPs net of placebo. Systolic BP reduction with losartan was more pronounced in whites (−15.5 mm Hg ± 2.6, P value Ͻ0.001) than in African-Americans (−5.8 mm Hg ± 1.5, P value = 0.003). The difference in changes in SBP between African-Americans and white subjects reached statistical significance (P value = 0.003). Similarly, DBP changes were more pronounced in whites (−7.3 mm Hg, ± 1.5, P value Ͻ0.001) than African-Americans (−3.5 mm Hg, ± 1.1, P value = 0.002). The difference in changes in DBP between African-Americans and white subjects reached statistical significance (P value = 0.045).
In this study, consumption of the DASH diet led to a significant reduction in SBP (−7.1 mm Hg, ± 3.2, P value = 0.025) compared with the control diet. African-Americans had a larger net reduction in SBP compared with whites (−8.5 ± 3.4, P value = 0.012 vs −3.0 ± 4.5, P value = 0.51), however, these differences were not significantly different from each other (P value = 0.32). Diastolic BP was also lowered with the DASH diet compared with controls (−3.0 ± 1.8, P value = 0.09). African-Americans on the d.) , except for PRA which is presented as geometric means and 95% CI. b n = 55 for all characteristics except, n = 48 for baseline fibrinolytic factors and n = 37 for baseline PRA. c Blood pressure is mean blood pressure measured at the end of run-in. DASH diet had a slightly larger net reduction in DBP than whites (−3.1 ± 1.8, P value = 0.09 vs −2.5 ± 2.4, P value = 0.31 respectively), although these differences were not significantly different from each other.
Effects of losartan on markers of fibrinolysis and PRA
Losartan significantly reduced plasma t-PA antigen compared with placebo (−1.8 ng/mL, P value = 0.045) ( Table 3 ). Among whites, the net reduction in t-PA antigen from losartan was 4.1 ng/dL (P = 0.003) compared with a 0.3 ng/mL reduction among African-Americans (P for interaction = 0.03). These changes were independent of the degree of BP reduction achieved, because adjustment for change in systolic or diastolic BP did not affect the results. There were no significant effects of losartan on either PAI-1 or t-PA enzyme activities and no significant effects on markers of fibrinolysis, overall or among African-Americans or white subjects separately.
Losartan significantly increased PRA in whites (+1.8 ng/mL/h, P Ͻ 0.001) but not African-Americans (−0.5 ng/mL/h, P = 0.1). The difference in PRA changes between African-Americans and whites was highly significant (P Ͻ 0.001).
Effects of the DASH diet on markers of fibrinolysis and PRA
The net effect of the DASH diet on markers of fibrinolysis and PRA was not significant (Table 4) . Furthermore, whites and African-Americans did not significantly differ in their response to the DASH diet with respect to fibrinolytic markers or PRA.
Discussion
In this trial, we documented that treatment with losartan results in significant reductions in t-PA antigen in white, but not African-American hypertensive individuals. To our knowledge, this is the first study to show a differential affect of AII blockade on markers of fibrinolysis in white and AfricanAmerican hypertensives. The DASH diet did not significantly affect markers of fibrinolysis in this study. This study has several strengths. All randomised participants completed the trial and the study sample contained a relatively high proportion of African-Americans, which allowed for assessment of differential effects of the treatments by race. In addition, this study was rigorously controlled, and because participants were fed their diet, we were able to assess the impact of losartan on fibrinolytic parameters while controlling sodium intake. Despite this, several aspects of the design and treatment should be considered in the interpretation of the results. Although we had sufficient power to address our primary study objective, we had less power to detect an effect of the DASH diet. However, studies that have demonstrated an impact of dietary factors on markers of fibrinolysis have been of similar size. While the duration of treatment with losartan was relatively short and the dose of losartan fixed in the current study, the effects of losartan on fibrinolyitic factors have been shown to occur within hours of receiving a single 50-mg dose. 16 In addition, higher doses of drugs that block the RAS are required to achieve a comparable level of BP reduction in African-Americans and whites. 31 Whether higher doses of losartan could produce similar changes in fibrinolytic parameters in African-Americans and whites is unknown. Additional studies are needed to clarify this issue.
Data regarding the effect of AII receptor blockade on t-PA antigen levels has been inconsistent. In one recent trial, treatment with losartan had no effect on t-PA antigen levels in persons with hypertension. 17 However, this trial was small and may have had insufficient power to detect small changes in t-PA antigen levels. In contrast, angiotensin II receptor blockade with losartan reduced t-PA antigen levels in healthy, normotensive individuals consuming very low and very high salt diets. Similarly, in persons with moderate congestive heart failure, a onetime dose of 50 mg of losartan acutely reduced t-PA antigen levels. 16 However, these studies were conducted in persons under conditions of external or physiologic RAS activation, and are not necessarily generalisable to more typical hypertensive individuals. In the current study, we have shown that t-PA antigen levels are reduced in otherwise healthy hypertensive individuals independent of dietary sodium intake. Our results are consistent with the hypothesis that AT1 receptor blockade is important in the regulation of t-PA antigen levels. However, we saw no significant effect of losartan on t-PA activity. Since active t-PA and PAI-1 enzymes are cleared more rapidly than the t-PA/PAI-1 complex, 34 it is possible that changes in t-PA antigen could occur independent of changes in enzyme activities. Finally, the lack of effect of losartan on PAI-1 enzyme activity in the current study is consistent with the hypothesis that effects of AII on PAI-1 are mediated by a non-AT1 receptor. 35 Few studies have examined the effect of dietary patterns on markers of fibrinolysis. The lack of effect of the DASH diet is consistent with previous studies that demonstrated no effect of a low-fat diet on t-PA antigen. 26, 27 Another strength of the current study is that we were able to rigorously control dietary sodium intake and body weight, two potentially important determinants of hemostasis. Thus, it is possible that concomitant changes in weight and/or sodium intake in prior dietary studies were more important than overall dietary patterns.
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The differential effect of losartan by race may be due to underlying differences in the level of RAS activation in whites and African-Americans. In this study and others, 30 PRA was lower in African-Americans compared with whites. Little is known about racial differences in fibrinolytic factors; however, whites have been found to have higher t-PA antigen levels than other racial groups and lower PAI-1 antigen levels than African-Americans. 36, 37 Consistent with these findings, we observed higher baseline levels of t-PA antigen in whites compared with African-Americans who were consuming the same control diet. Thus, lower levels of t-PA antigen in African-Americans in this study are not likely due to differences in dietary patterns or salt intake.
Additional evidence that underlying RAS differences between African-Americans and white subjects could account for differences in the fibrinolytic profile between races comes from our observation of a significantly greater increase in PRA with losartan treatment in whites compared with African-Americans. Since the rise in PRA accompanying AT1 receptor blockade is due to release of negative feedback of AII on renin release (short-feedback loop) it is possible that this differential rise in PRA reflects altered regulation of renin release in African-Americans or a greater effect of RAS inhibition in whites, although these hypotheses were not directly tested in the current study.
Several studies have demonstrated that elevated t-PA antigen increases the risk of cardiovascular (CVD) events. 20, 38, 39 In addition, t-PA antigen is a stronger predictor of future outcomes than PAI-1 antigen or activity. 19, 40, 41 The paradoxical association of increased risk of CVD events and increased t-PA antigen is likely due to the fact that t-PA clearance is largely dependent on PAI-1. 34 Because most circulating t-PA antigen is bound to PAI-1, elevated levels of t-PA antigen likely reflect resistance to fibrinolysis. The results of this study suggest that favourable effects on fibrinolytic factors may mediate some of the reduction in cardiovascular disease risk obtained from pharmacologic inhibition of AII.
In conclusion, hypertensive patients treated with losartan have significant reductions in t-PA antigen whereas the DASH diet had no effect on markers of fibrinolysis. This effect of losartan was seen in white, but not African-American hypertensive individuals. The differential effect of losartan by race may reflect underlying racial differences in the level of activity of the RAS or response to RAS inhibition. Ultimately, large-scale studies with clinical endpoints are needed to determine whether reducing t-PA antigen reduces cardiovascular disease risk.
